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Polymorphisms in the human endothelial nitric oxide synthase
(eNOS) gene (NOS3) have been associatedwith advanced nephrop-
athy in diabetic patients and with decreased expression in tissue
culture. However, direct proof that modest genetic decreases in
eNOS expression worsen diabetic nephropathy is lacking. To inves-
tigate this effect, we took advantage of the hybrid vigor and ge-
netic uniformity of the F1 progeny (eNOS+/+, eNOS+/−, or eNOS−/−
with or without diabetes) of a cross between heterozygous 129S6/
SvEvTac eNOS+/− inbred females and heterozygous C57BL/6J
eNOS+/− inbred males carrying the dominant Akita diabetogenic
mutation Ins2C96Y/+. Whereas all C57BL/6J inbred eNOS−/− and
eNOS+/− diabetic mice died before 5 mo, almost half of the F1 hy-
brid eNOS−/− and eNOS+/− diabetic mice lived until killed at 7 mo.
Heterozygous eNOS+/− diabetic mice expressed ∼35% eNOSmRNA
in the kidney and ∼25% glomerular eNOS protein relative to their
eNOS+/+ diabetic littermates. These decreases in eNOS elevated
blood pressure (BP) but not blood glucose. Urinary albumin excre-
tion, mesangial expansion, glomerulosclerosis, mesangiolysis, and
glomerular filtration rate increased in the order: eNOS+/+ Akita <
eNOS+/− Akita < eNOS−/− Akita, independently of BP. Glomerular
basement membrane thickening depended on increased BP. Renal
expression of tissue factor and other inflammatory factors in-
creased with the nephropathy; Nos2 also increased. Surprisingly,
however, decreased eNOS expression ameliorated the increases in
oxidative stress and tubulointerstitial fibrosis caused by diabetes.
Our data demonstrate that amodest decrease in eNOS, comparable
to that associated with human NOS3 variants, is sufficient to en-
hance diabetic nephropathy independently of its effects on BP.
diabetic complications | heterozygotes
Diabetic nephropathy (DN) is the most frequent cause ofchronic kidney disease and is a risk factor for stroke and
heart attack (1). Clinical studies indicate that 30–40% of diabetic
patients develop DN (2). The development and severity of DN
vary greatly from one patient to another, and familial clustering
suggests that genetic factors play important roles (3). In humans,
three variants in the endothelial NOS (eNOS) gene NOS3 (i.e,
G894T in exon 7, a different number of tandem repeats in intron
4, and C-786T in the promoter) are associated with DN (4–6). Of
these variants, the G894T (Glu298Asp) polymorphism has been
particularly well studied, because the frequency of the 894T al-
lele is around 0.3 (4, 7), so that 5–9% of individuals are homo-
zygous for TT. The 894T NOS3 gene produces about 30% of the
amount of NO produced by the more common 894G allele when
expressed in CHO cells in vitro (4). Although complete absence
of eNOS accelerates DN in mice (8–11), this result does not
tell us whether production of eNOS at reduced levels compa-
rable to those associated with the NOS3 polymorphisms is suf-
ficient to worsen DN. To investigate this possibility, we first
crossed C57BL/6J (B6) female eNOS+/− heterozygous mice with
B6 males heterozygous for both the eNOS disruption (eNOS+/−)
and the diabetogenic Akita mutation (Ins2C96Y/+). However, this
experiment failed because the inbred eNOS−/− and eNOS+/−
diabetic males died before the age of 5 mo. We therefore de-
cided to take advantage of the hybrid vigor of F1 mice, which are
as genetically uniform as inbred mice but lack most of the detri-
mental recessive mutations that affect the survival of their inbred
parents. Accordingly, we crossed 129S6/SvEvTac (129) inbred
females heterozygous for the eNOS disruption (eNOS+/−) with B6
eNOS+/− heterozygous inbred males having the Akita mutation
and studied their progeny. The results of studying these hybrid F1
mice demonstrate that a modest decrease in eNOS, comparable
to that associated with humanNOS3 variants, is sufficient to cause
exacerbated DN independent of its effects on BP.
Results
Survival of F1 (B6 × 129) Heterozygous eNOS+/− Akita Mice. We first
attempted to generate eNOS−/− and eNOS+/−Akita diabetic mice
on the inbred B6 genetic background, but this experiment failed
because all the eNOS−/− and eNOS+/− diabetic males died before
age 5 mo. To take advantage of the hybrid vigor of F1 mice, which
are as genetically uniform as inbred mice but lack most of the
detrimental recessive mutations that affect the survival of inbred
strains, we crossed 129 inbred females heterozygous for the eNOS
disruption (eNOS+/−) with B6 eNOS+/− heterozygous inbred
males also having the Akita mutation (Ins2C96Y/+) and studied
their F1 progeny. The progeny include all six possible genotypes:
eNOS+/+, eNOS+/−, and eNOS−/−, with or without the dominant
Akita diabetogenic mutation. Eleven of 21 eNOS+/− Akita mice
(52%), 8 of 17 eNOS−/− Akita mice (47%), and all mice of the
other genotypes survived until they were killed at age 7 mo for
detailed study (Fig. 1). We were unable to determine the cause of
death of the mice that died before age 7 mo, but occasional
bleeding within the chest or abdominal cavity was observed, and
many of the deceased mice appeared to have been dehydrated.
The basic parameters of the six groups of mice at age 3 mo and
age 7 mo are summarized in Tables S1 and S2. Blood glucose
levels, food and water intake, and urine volume were all signif-
icantly elevated (P ≤ 0.002) in the diabetic mice compared with
their nondiabetic littermates. In contrast, no significant effects
of eNOS genotype on these parameters were observed, but tail-
cuff blood pressure (BP) increased progressively in the order:
eNOS+/+ < eNOS+/− < eNOS−/− at both 3 and 7 mo of age,
demonstrating a strong eNOS genotype effect (P < 0.0001). The
BPs of the diabetic mice were indistinguishable from those of
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nondiabetic mice with the same eNOS genotype at age 3 mo.
However, at age 7 mo the BP of the diabetic mice of all eNOS
genotypes was higher than the BP of nondiabetic mice of the
same genotypes, showing an age-dependent effect of diabetes on
BP (P < 0.01). Together these results show that an absence or
decrease of eNOS in diabetic mice elevates BP and decreases
survival without affecting plasma glucose levels.
Expression of Kidney eNOS. The kidneys from eNOS+/− mice
expressed 49 ± 8% eNOS mRNA compared with eNOS+/+ mice
when tested by quantitative RT-PCR, whereas kidneys from
eNOS−/− mice did not express eNOS mRNA (Fig. 2A). Diabetes
decreased eNOS mRNA levels to approximately half those in
nondiabetic mice, with the expression in eNOS+/− diabetic kid-
neys being 35% of that in their eNOS+/+ diabetic littermates
(Fig. 2A). Immunostaining against eNOS showed that all glo-
meruli were positive for eNOS in WT mice and that all glomeruli
were negative for eNOS in the eNOS−/− mice (Fig. 2B). Ap-
proximately 30% of glomeruli in eNOS+/− mice show no de-
tectable immunoreactivity for eNOS, and the other glomeruli
have fewer eNOS-positive cells than glomeruli in WT mice,
rather than having half the intensity per cell. We estimate that
glomeruli from eNOS+/− mice express 32 ± 6% eNOS protein
immunoreactivity relative to glomeruli from eNOS+/+ mice (Fig.
2C). Diabetes decreased glomerular eNOS protein to approxi-
mately half that of nondiabetic mice, with the protein expression
in eNOS+/− diabetic kidneys being ∼25% of that in their eNOS+/+
diabetic littermates (Fig. 2C). We conclude that the expression
levels of eNOS mRNA and protein in the kidneys of heterozy-
gous eNOS+/− mice are ∼35–50% of the levels in WT mice.
Diabetes decreases the expression of both mRNA and protein of
eNOS in the kidney by about 50%, but in the heterozygous
eNOS+/− diabetic mice expression is still ∼25–35% of that in WT
diabetic mice.
Renal Function and Morphology. In nondiabetic F1 mice, complete
absence of eNOS in the eNOS−/− mice significantly increases
urinary albumin excretion compared with WT mice; in contrast,
the reduction of eNOS seen in the heterozygous eNOS+/− mice
has no effect (Fig. 3A). However, when the mice were Akita di-
abetic, the reduction of eNOS in the heterozygous eNOS+/−Akita
mice was sufficient to increase urinary albumin excretion above
that in eNOS+/+ Akita mice. Thus, at both 3 and 7 mo of age,
urinary albumin excretion in eNOS+/− Akita and eNOS−/− Akita
mice was∼2.5 times higher than in eNOS+/+ Akita mice (186± 20
μg/d and 212 ± 21 μg/d vs. 82 ± 15 μg/d at 7 mo) (Fig. 3A).
The glomerular filtration rate (GFR), estimated by endoge-
nous creatinine clearance, in nondiabetic eNOS−/− mice was
greater than in WT mice at 3 mo of age but was less than in WT
mice at 7 mo (Fig. 3B). The GFR in diabetic mice was increased
progressively by both reduction and absence of eNOS at 3 mo
(eNOS+/+ Akita < eNOS+/− Akita < eNOS−/− Akita). At age 7
mo the GFR of eNOS+/− Akita mice increased further, although
that of eNOS−/− Akita mice was lower than at age 3 mo (Fig.
3B). We conclude that the increase in the GFR caused by di-
abetes is increased further by the decrease in eNOS that occurs
in the eNOS+/− Akita mice.
Kidney sections and morphometric analyses of the glomeruli
(Fig. 4) showed no notable effects of the eNOS genotype in
nondiabetic mice, but in the diabetic mice the classical changes
associated with DN, including mesangial expansion (Fig. 4B),
mesangiolysis (Fig. 4C), glomerulosclerosis (Fig. 4D), and glo-
merular basement membrane (GBM) thickening (Fig. 4E),
were progressively more severe in the order: eNOS+/+ Akita <
eNOS+/− Akita < eNOS−/− Akita mice. In contrast, as judged by
EM morphology, the podocytes and endothelial cells of the
eNOS+/− Akita and eNOS−/− Akita mice were unremarkable
compared with those of eNOS+/+ Akita mice, although the
progressive increases in GBM thickness in the eNOS+/− and
eNOS−/− diabetic mice was easily seen (Fig. 4A, Bottom). Not
surprisingly, a mild degree of tubulointerstitial fibrosis is appar-
Fig. 1. Survival rates of male F1 (C57BL/6J × 129S6/SvEvTac) Akita (Ins2Akita/+,
A) diabetic mice with eNOS genotypes +/+ (solid line), +/− (dotted line), and −/−
(dashed line). All nondiabetic mice, regardless of eNOS genotype, survived
until the end of the experiment.
Fig. 2. Renal eNOS mRNA and protein expression in 7-mo-old F1 (C57BL/6J ×
129S6/SvEvTac) mice. (A) eNOS gene expression in the kidney. (B) Represen-
tative immunoreactive eNOS in the glomeruli. (C) Summary of the quantity of
immunoreactive eNOS in the glomeruli. A, Ins2Akita/+. +/+, +/−, and −/− designate
eNOS genotypes. a, P < 0.05 vs. eNOS+/+; b, P < 0.05 vs. eNOS+/−; c, P < 0.05 vs.
eNOS−/−; d, P < 0.05 vs. eNOS+/+ A; e, P < 0.05 vs. eNOS+/− A. Data are mean ±
SEM. n ≥ 8. Note that diabetes decreases eNOSmRNA and protein expression.
Effects on eNOS mRNA and protein levels of diabetes, eNOS genotype, and
their interaction were all significant (P < 0.01, P < 0.0001, and P < 0.05, re-
spectively, for eNOS mRNA; P < 0.01, P < 0.001, and P < 0.02, respectively for
eNOS protein).
Fig. 3. Renal function of F1 mice with different eNOS genotypes and Akita
mutation. (A) Daily urinary albumin at age 3 mo and 7 mo. At age 3 mo and
7 mo the effects on daily albumin excretion of diabetes, eNOS genotype, and
their interaction were all significant (P < 0.001, P < 0.001, and P < 0.03,
respectively). (B) GFR estimated by creatinine clearance at age 3 mo and
7 mo. The effects on GFR of diabetes, eNOS genotype, and their interaction
were all significant at age 3 mo (P < 0.001, P < 0.001, and P < 0.05, re-
spectively) but at age 7 mo were P < 0.001, P = 0.1, and P = 0.9, respectively.
Data are mean ± SEM. n ≥ 8. A, Ins2Akita/+. +/+, +/−, and −/− designate eNOS
genotypes. a, P < 0.05 vs. eNOS+/+; b, P < 0.05 vs. eNOS+/−; c, P < 0.05 vs.
eNOS−/−; d, P < 0.05 vs. eNOS+/+ A; e, P < 0.05 vs. eNOS+/− A. *P < 0.05 vs.
values in the same mice at age 3 mo.











ent in the eNOS+/+ Akita diabetic mice but not in the eNOS+/+
WT nondiabetic mice; surprisingly, however, partial or complete
absence of eNOS expression in the eNOS+/− Akita and eNOS−/−
Akita mice prevented this fibrosis (Fig. 4F).
Urinary albumin excretion and mesangial score were highly
correlated with BP (R2 = 0.68, P < 0.001, and R2 = 0.56, P =
0.002, respectively) but not with blood glucose levels (R2 = 0.5,
P = 0.3, and R2 = 0.05, P = 0.94, respectively) (Fig. S1). The
strong correlations between these indicators of DN and in-
creased BP raise questions about the degree to which the en-
hanced DN is a direct effect of reduced eNOS or is secondary to
the increased BP resulting from decreased eNOS. Accordingly,
we used partial regression leverage plots to separate statistically
the effects of BP and of genotype on six classical parameters of
DN (urinary albumin excretion, mesangial expansion, GBM
thickening, glomerulosclerosis, mesangiolysis, and GFR). The
results of this analysis are presented in Table S3, which shows
that at age 7 mo the overall effects of the reduced expression
of eNOS with the change in eNOS genotype (eNOS+/+ versus
eNOS+/−) are highly significant for all parameters (P ≤ 0.005),
except that the effect on GFR is detectable only at age 3 mo (P <
0.04). The mesangial expansion is caused in part indirectly by the
effects of decreased eNOS on BP (P= 0.01) and in part by direct
effects of this decrease (P = 0.02). The GBM thickening is
caused mainly by the indirect effects of increased BP (P =
0.008). The increases in albumin excretion (P = 0.01), glomer-
ulosclerosis (P = 0.01), and mesangiolysis (P < 0.001) are caused
mainly by the direct effects of the decreased eNOS. Together
these results demonstrate that the decrease of eNOS seen in
eNOS+/− heterozygous diabetic mice is sufficient to exacerbate
the functional and morphological changes of DN, in part directly
and in part indirectly through increased BP.
Fibrin, Tissue Factor, and Inflammation in the Kidney. NO inhibits
coagulation (12), and diabetes leads to fibrin deposition in glo-
meruli (13). eNOS−/− mice made diabetic by low doses of strep-
tozotocin have increased fibrin deposition and tissue factor (TF,
F3) expression in their glomeruli (11). Accordingly, we examined
fibrin deposition and TF expression in the kidneys of Akita di-
abetic mice. As expected, the eNOS+/− Akita and eNOS−/− Akita
mice had more immunoreactive fibrin in their glomeruli than did
Akita mice having WT eNOS (Fig. 5A). eNOS+/− Akita mice and
eNOS−/− Akita mice also had increased renal TF (F3) mRNA
levels and activities as compared with eNOS+/+ Akita mice (Fig. 5
B and C). Expression of F4/80 (Emr1), a macrophage marker,
paralleled the TF expression (Fig. 5D). The glomeruli of the di-
abetic eNOS+/− Akita mice and eNOS−/− Akita mice showed
prominent TF immunoreactivity colocalized with monocytes/
Fig. 4. Histology of F1 mice with different eNOS genotypes (eNOS+/+, eNOS+/−, and eNOS−/−) and Akita mutation. (A) Representative kidney morphology of
7-mo-old diabetic mice with different eNOS genotypes. (Top) PAS stain (100×). Yellow arrow indicates mesangial expansion; open arrows indicate mesan-
giolysis; yellow arrowhead indicates glomerulosclerosis. (Middle) Glomeruli with Masson Trichrome stain (200×). (Bottom) Transmission electron micrographs
with original magnification of 12,500×. (B–F) Quantification of mesangial expansion (B), mesangiolysis (C), glomerulosclerosis (D), GBM thickening (E), and
tubulointerstitial fibrosis score (F) of 7 mo-old mice. There was no glomerulosclerosis or mesangiolysis in any nondiabetic mice, regardless of eNOS genotype.
A, Ins2Akita/+. +/+, +/−, and −/− designate eNOS genotypes. Data are mean ± SEM. n ≥ 8. a, P < 0.05 vs. eNOS+/+; b, P < 0.05 vs. eNOS+/−; c, P < 0.05 vs. eNOS−/−; d,
P < 0.05 vs. eNOS+/+ A; e, P < 0.05 vs. eNOS+/− A. Effects on mesangial expansion and GBM thickness of diabetes, eNOS genotype, and their interaction were all
significant (P < 0.001, P < 0.001, and P < 0.05, respectively).
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macrophages (Fig. 5E). Although the kidneys of the nondiabetic
mice were negative for immunoreactive TF irrespective of their
eNOS genotype, all cells in the diabetic kidneys that were positive
for TF were monocytes/macrophages, as judged by monocyte/
macrophage marker (MOMA-2) reactivities. All MOMA-2+ cells
were positive for TF.
NO is able to attenuate inflammation (12). Inflammation
increases expression of TF, and TF induces inflammation (14). It
also is well known that diabetes leads to inflammation and fibrosis
(15, 16). We therefore studied the renal expression of in-
flammatory and fibrogenic genes (Fig. 6 and Table S4). In the
eNOS+/− Akita kidneys the expression of many of these genes,
including Tnf, Il-6, monocyte chemotactic protein 1 (Mcp1), in-
tercellular adhesion molecule 1 (Icam1), vascular cell adhesion
molecule 1 (Vcam1), Tgfb, and type 4 collagen (Col4), was signif-
icantly higher than in the eNOS+/+ Akita kidneys. The expression
of Il-6,Mcp1, Icam1, Vcam1, Tgfb, and Col4 in the eNOS+/−Akita
kidneys was as great as in the eNOS−/− Akita kidneys (Fig. 6).
We next tested whether parameters of DN and levels of
gene expression are associated. Urinary albumin excretion and
mesangial score were highly correlated with the expression of F3
and Tnf (Fig. S2 A–D). The expression of F3 and Tnf and BP also
were highly correlated with each other (Fig. S2 E–G). The ex-
pression of other inflammatory markers (Il-6, Mcpt1, Icam1, and
Vcam1) also was highly correlated with urinary albumin excre-
tion and mesangial score (not shown for clarity). We conclude
that decreases in eNOS increase renal expression of TF (F3) and
inflammatory genes, in parallel with an exacerbation of DN.
Oxidative Stress and Inducible NOS. Localized increases in oxida-
tive stress have been postulated to be key components in the
development of DN (17). Glutathione (GSH) plays a critical role
in cellular defense against oxidative stress in tissues and cells. In
our nondiabetic mice, the level of reduced GSH and the ratio of
GSH to its oxidized form (GSH/GSSG) in the kidneys of
eNOS+/− mice were indistinguishable from those in eNOS+/+
mice, although GSH level and GSH/GSSG ratio were decreased
in eNOS−/− mice (Fig. S3). Not surprisingly, these parameters
were decreased in the WT mice made diabetic by the Akita
mutation. Surprisingly, however, the kidneys of eNOS+/− Akita
and eNOS−/− Akita diabetic mice had significantly higher levels
of GSH (P = 0.003 and 0.001, respectively) and higher GSH/
GSSG ratios (P= 0.002 and 0.001, respectively) than did kidneys
in eNOS+/+ Akita mice. Because increases in GSH levels and
GSH/GSSG ratios are indicators of reduced oxidative stress,
these data show that reduced eNOS actually decreases the oxi-
dative stress induced by diabetes (Fig. S3). We therefore exclude
increased oxidative stress as a factor in the exacerbation of DN
resulting from reduced eNOS.
We also tested whether changes in renal inducible NOS
(iNOS; Nos2) expression are involved in the pathogenesis of DN
when the expression of eNOS decreases. We find that renal ex-
pression of Nos2 is greater in the eNOS+/− Akita mice than in
the eNOS+/+ Akita mice (P = 0.03) (Fig. S4A). However, uri-
nary NO metabolites (NOx) excretion, an indicator of total NO
production in an animal, is significantly less in eNOS+/− Akita
mice than in eNOS+/+ Akita mice (P = 0.003) (Fig. S4B). We
conclude that the increased expression of iNOS that occurs in
the eNOS+/− Akita mice is not sufficient to prevent an overall
decrease in NO production.
Discussion
Three NOS3 polymorphisms are associated with the de-
velopment of severe DN and with a decrease in NO production
in some tissue culture experiments (4–6). Several previous
studies using homozygous eNOS−/− diabetic mice, including ours,
have demonstrated that absence of eNOS worsens DN (8–11).
However, there have been no reports of humans homozygous
for absence of eNOS. Consequently the phenotype of eNOS−/−
diabetic mice does not tell us whether reduced NO production,
as associated with the NOS3 polymorphisms, is sufficient to ex-
acerbate DN. Our experience with mice shows that in some
cases, even when homozygous knockouts (−/−) have a profound
Fig. 5. Fibrin deposition, TF (F3) expression, and macrophage infiltration in
the kidneys of 7-mo-old mice. (A) Immunostaining against fibrin in kidney
glomeruli from diabetic mice (100×). Kidneys from all nondiabetic mice,
regardless of eNOS genotype, were negative for fibrin. (B and C) Kidney TF
(F3) mRNA levels relative to eNOS+/+ mice (B) and kidney TF activity (C). (D)
Expression of a macrophage marker, F4/80 (Emr1), in the kidney relative to
eNOS+/+ A. Effects on TF expression of diabetes, eNOS genotype, and their
interaction were all significant (P < 0.004, P < 0.001, and P < 0.02, re-
spectively). A, Ins2Akita/+. +/+, +/−, and −/− designate eNOS genotypes. a, P <
0.05 vs. eNOS+/+; b, P < 0.05 vs. eNOS+/−; c, P < 0.05 vs. eNOS−/−; d, P < 0.05 vs.
eNOS+/+ A; e, P < 0.05 vs. eNOS+/− A. (E) Immunostaining of kidney glomeruli
against TF and monocytes/macrophages (MOMA-2) in diabetic mice (100×).
DIC, differential interference contrast. There was no significant immunos-
taining of TF or MOMA-2 outside glomeruli (in the tubulointerstitial com-
partment).
Fig. 6. mRNA expression of inflammatory and fibrogenic genes in the
kidney of 7-mo-old diabetic mice. A, Ins2Akita/+. +/+, +/−, and −/− designate
eNOS genotypes. Values are relative to +/+ A. d, P < 0.05 vs. eNOS+/+ A; e, P <
0.05 vs. eNOS+/− A. The expression of the genes of six groups of mice, in-
cluding nondiabetic mice, is shown in Table S4.











phenotype, the heterozygous knockouts (+/−) and WT (+/+) can
be indistinguishable, as occurs with disruption of the furosemide-
sensitive NaK2Cl cotransporter NKCC2 (18, 19) and of renin
(Ren1c) (20). However, in other cases, such as the natriuretic
peptide receptor A (Npr1), the phenotype of heterozygous
knockout mice is readily distinguishable from that of WT (21).
Our present study accordingly was aimed at removing uncertainly
about whether the mild genetic decrease in eNOS expression
which occurs in eNOS+/− mice is sufficient to cause DN.
The mice used in our study were F1 mice obtained from crosses
between inbred B6 doubly heterozygous males (eNOS +/− and
Ins2Akita/+) and inbred 129 heterozygous females (eNOS +/−). F1
progeny usually are more vigorous than inbred mice, because they
lack many of the detrimental recessive mutations that can affect
inbred strains, and we found that the B6/129 F1 eNOS+/− and
eNOS−/− diabetic mice survived much longer than the equivalent
inbred mice. Thus, although the life spans of the eNOS+/− di-
abetic F1 mice were reduced compared with their diabetic sib-
lings with WT eNOS (Fig. 1), sufficient numbers survived to age
7 mo, at which time they were killed for study. It is important to
note that F1 mice generated by crossing two different inbred
mouse lines are as genetically uniform as human monozygotic
twins. Note also that by bringing in the dominant Akita di-
abetogenic allele from the male parent, problems associated with
fetal development in a hyperglycemic environment are avoided.
Another advantage of this breeding scheme is that it avoids using
potentially debilitated homozygous mutants as breeders, but the
progeny include all six possible combinations of the genes of in-
terest (eNOS+/+, eNOS+/−, and eNOS−/− with and without the
dominant Akita allele), including homozygous mutants and WT
controls. This complete coverage, combined with the genetic
uniformity of the progeny, enables the detection of subtle or
unexpected differences, as discussed below, some which can be
missed when only a subset of the possible genotypes is studied.
Using these F1 mice, we showed that the expression of eNOS
mRNA and protein in the kidneys of heterozygous eNOS+/−
nondiabetic and diabetic mice was 25–50% that of their eNOS+/+
nondiabetic and diabetic littermates (Fig. 2). These levels of re-
nal eNOS expression in the eNOS+/− nondiabetic and diabetic
mice are comparable to the NO production observed in some
tissue culture experiments with NOS3 894T and NOS3 894G
transgenes (∼30%). Thus, our eNOS+/− mice provide an excel-
lent model with which to test whether a mild decrease in NO
production comparable to that observed in the NOS3 G894T
polymorphism can exacerbate DN.
Our results demonstrate that six primary parameters of DN—
mesangial expansion, mesangiolysis, glomerulosclerosis, GBM
thickening, albuminuria, and changes in GFR—were pro-
gressively enhanced in the order: eNOS+/+ Akita < eNOS+/−
Akita < eNOS−/− Akita (Figs. 3 and 4). The modest decrease of
eNOS seen in eNOS+/− heterozygotes is sufficient to exacerbate
all these functional and morphological indicators of DN.
Among the parameters of DN, GFR deserves particular com-
ment. Typically diabetes first increases GFR and later decreases
GFR to below normal. The Akita diabetic mutation in combina-
tion with complete absence of eNOS shows this trend (Fig. 3B).
Thus, GFR is markedly increased in the eNOS−/− Akita mice at
age 3 mo but is decreased at age 7 mo. GFR in the eNOS+/−Akita
mice increases between age 3 mo and 7 mo, as might be expected
whenDN is developing but is not yet full blown, and is significantly
greater at both ages than in their eNOS+/+ Akita littermates.
Our data with F1 hybrid mice show that the decreased ex-
pression of eNOS in the eNOS+/− mice and its absence in the
eNOS−/− mice have marked effects on inflammatory determi-
nants, as indicated by significant increases in renal expression of
TF and several other inflammatory genes (Figs. 5 and 6). Fur-
thermore, in a previous study of B6 mice made diabetic by low-
dose streptozotocin, we showed that anti-TF neutralizing anti-
body decreases renal expression of inflammatory and fibrogenic
genes (11). This increase in TF in the eNOS+/− Akita mice may
be one of the ways whereby decreased expression of eNOS
worsens DN.
In this context, it is notable that B6 mice made diabetic by
streptozotocin develop variable degrees of tubulointerstitial fi-
brosis (11, 22). In agreement with this result, we find that our
eNOS+/+ Akita diabetic mice developed mild tubulointerstitial
fibrosis at age 7 mo (Fig. 4F). Surprisingly, however, there was less
tubulointerstitial fibrosis in eNOS+/− Akita mice and eNOS−/−
Akita mice than in the eNOS+/+ Akita mice and indeed was less
than in the nondiabetic eNOS WT mice. We conclude that a de-
crease in eNOS does not enhance the tubulointerstitial fibrosis
induced by diabetes.
Oxidative stress has been suggested as contributing to DN
(17). Not-surprisingly, therefore, we find that diabetes in the
eNOS+/+ Akita mice is accompanied by a decrease in GSH
levels and GSH/GSSG ratios, indicating increased oxidative
stress. Surprisingly, however, we find that the increased oxidative
stress caused by diabetes in the eNOS+/+ Akita mice is de-
creased by reduced expression of eNOS (Fig. S3), indicating that
a decrease in eNOS is protective in this aspect of DN. Indeed,
as judged by these indicators, the oxidative stress of the dia-
betic mice with a decreased level or absence of eNOS is less than
that of the completely WT nondiabetic mice. This observation
emphasizes the value of having a comprehensive set of geneti-
cally uniform mice to study the effects of genotype on a delete-
rious condition. We therefore exclude increased oxidative stress
as a factor in the exacerbation of DN resulting from reduced
expression of eNOS. Renal expression of Nos2 is greater in the
eNOS+/−Akita mice than in the eNOS+/+Akita mice. However,
these increases are not sufficient to prevent decreased pro-
duction of NO in the eNOS+/−Akita mice, as judged by the re-
duced urinary excretion of NOx.
Our present data from F1 mice show, in agreement with
previous observations (23), that BP is markedly affected by
changes in the expression of eNOS, and that the BP of the F1
mice correlates strongly with many of the measures of DN, in-
cluding albumin excretion, mesangial score, and renal expression
of F3 and Tnf. Furthermore, in human patients, BP is a major
determinant of the risk of developing DN (20). Additionally,
decreasing BP using hydralazine ameliorates the DN that
develops in eNOS−/− mice made diabetic by streptozotocin (24).
These observations raised the possibility that the highly signifi-
cant effects of modestly decreased eNOS expression on DN that
we have documented here could be mainly the consequence
of increased BP. To evaluate this possibility, we tabulated the
overall effects at age 7 mo of the eNOS+/− genotype on six
classical indicators of DN (urinary albumin excretion, mesangial
expansion, GBM thickening, glomerulosclerosis, mesangiolysis,
and GFR) and by statistically separating the effects of BP and of
genotype using partial regression leverage plot analysis (Table
S3). The results of this statistical analysis are unequivocal: At age
7 mo the overall effects of the reduced eNOS are highly signif-
icant for all indicators, except that the effect on GFR is de-
tectable only at age 3 mo. The mesangial expansion is caused in
part indirectly by the effects of decreased eNOS expression on
BP but also is caused in part by the direct effects of this decrease
in eNOS. The GBM thickening is caused mainly by the indirect
effects of increased BP. The increases in albumin excretion are
caused mainly by direct effects of the decreased eNOS, as are
glomerulosclerosis (P = 0.01) and mesangiolysis (P < 0.001).
Thus, by using genetically uniform and robust B6/129 hybrid
F1 mice, we have shown that a modest decrease in eNOS,
comparable to that associated with polymorphisms in the human
NOS3 gene, markedly enhances the development of diabetic
nephropathy. Most of the damaging effects are independent of
changes in blood pressure.
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Methods
Animals. All animal experiments were conducted in accordance with the
guidelines of the Institutional Animal Care and Use Committee at the Uni-
versity of North Carolina at Chapel Hill. Mice having the null allele for the
eNOS gene were developed originally in 129/Ola ES cells (25) and transferred
to a C57BL/6J genetic background by backcrossing to WT C57BL/6J at least six
times. Subsequently the mutation was transferred to the 129S6/SvEvTac
background by serial backcrossing for at least 12 generations. By mating
eNOS+/− Akita male mice on a C57BL/6J background with eNOS+/− female
mice on a 129S6/SvEvTac background, we generated F1 eNOS+/+, eNOS+/−,
and eNOS−/− mice with and without the Akita diabetogenic mutation. Ani-
mals were fed a regular chow, Prolab IsoproRMH3000 5P00 (14% calories
from fat), and were maintained without insulin treatment for 7 mo. At age 3
mo and age 7 mo, individual mice were placed in metabolic cages designed
by Thomas Coffman (Duke University, Durham, NC), and 24-h urine was
collected for two consecutive days (11, 20, 23). Body weight, food and water
intake, and urine volume were measured every 24 h. Usually, when the study
is carried out in the room in which the mice have been housed in regular
cages, or when mice are acclimatized in the study room for 1 wk before
being housed in metabolic cages, there is no significant difference in urine
volume and daily urinary albumin excretion between the first and second
day of collection. We measured daily urinary albumin excretion and creati-
nine clearance using the second 24-h sample and blood drawn at the end of
48-h study. If there was a change in body weight >10%, samples were ex-
cluded from the study.
Measurement of BP and GFR. BP was measured in 3- and 7-mo-old mice by the
computerized tail-cuff method we have developed in the laboratory (Visi-
tech) (20, 26). All measurements were taken in the morning, and the first 10
of the 60 measurements taken each day were discarded to obtain data after
the mice were acclimatized to the equipment. BP was measured for 5 d, and
the mean values of individual mice were used for analysis. GFR was esti-
mated by creatinine clearance. Plasma and urinary creatinine concentrations
were measured using LC-MS/MS (27).
Biochemical Measurements. Urinary albumin was determined using Albuwell-
M kits (Exocell). Kidney GSH and GSSH levels were measured by GSH assay kit
(Cayman Chemical). TF activity was measured as previously described (11, 28).
Quantitative RT-PCR. Gene expression in the kidney cortex was quantified
with TaqMan real-time quantitative RT-PCR (Applied Biosystems) with β-actin
as a reference gene, as we previously described (11, 20). Primers and probes
used are listed in Table S5.
Kidney Morphometry and Immunohistochemistry. Cross-sections of kidneys
containing papilla (5-μm-thick paraffin) were stained with periodic acid-
Schiff (PAS) or with Masson’s Trichrome and analyzed (11, 20). Monoclonal
rat anti-mouse TF antibody (1H1) was kindly provided by Daniel Kirchhofer
(Genentech, South San Francisco, CA) (29). eNOS protein levels were de-
termined by immunostaining using rabbit anti-mouse eNOS antibody
(Thermo Fisher Scientific) and semiquantified using Image J (11, 2).
Statistical Analysis. Data are expressed as mean ± SEM. Multifactorial ANOVA
with the program JMP 8.0 (SAS Institute) was used to compare the effects of
eNOS genotype and diabetes. The Tukey–Kramer Honestly Significant Dif-
ference (HSD) test was used for post hoc comparisons between each group.
P < 0.05 was considered statistically different. Partial regression lineage plot
analyses to separate the direct effects of eNOS genotype on DN from in-
direct effects caused by changes in BP were performed with the program
JMP 8.0 (SAS Institute).
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